Clinical Utility of Preoperative Vitamin D3 Injection for Preventing Transient Hypocalcemia after Total Thyroidectomy
Table 6
Subgroup analysis between vitamin D3 injection (VDI) and vitamin D3 noninjection (VDN) groups according to the 25-OHD levels.
25-OHD levels (0∼10 ng/mL)
VDI (n = 34)
VDN (n = 151)
value
Age (years)
43.8 ± 13.2 (range, 20–65)
45.5 ± 12.5 (range, 16–80)
0.487
Female
26 (76.5%)
141 (93.4%)
0.007
Multifocality
20 (58.8%)
80 (53.0%)
0.573
Bilaterality
14 (41.2%)
62 (41.1%)
0.569
ETE
7 (20.6%)
23 (15.2%)
0.012
Transient hypocalcemia
8 (23.5%)
44 (29.1%)
0.673
25-OHD levels (10∼20 ng/mL)
VDI (n = 240)
VDN (n = 920)
value
Age (years)
44.0 ± 12.9 (range, 12–78)
44.3 ± 13.1 (range, 14–84)
0.715
Female
175 (72.9%)
722 (78.5%)
0.070
Multifocality
131 (54.6%)
529 (57.5%)
0.422
Bilaterality
100 (41.7%)
427 (46.4%)
0.191
ETE
43 (17.9%)
164 (17.8%)
0.988
Transient hypocalcemia
49 (20.4%)
275 (29.6%)
0.006
25-OHD levels (20∼30 ng/mL)
VDI (n = 59)
VDN (n = 676)
value
Age (years)
44.8 ± 15.5 (range, 19–81)
49.9 ± 13.8 (range, 12–82)
0.007
Female
47 (79.7%)
503 (74.4%)
0.436
Multifocality
37 (62.7%)
389 (57.5%)
0.493
Bilaterality
30 (50.8%)
310 (45.9%)
0.497
ETE
11 (18.6%)
121 (17.9%)
0.747
Transient hypocalcemia
7 (11.9%)
189 (27.9%)
0.004
Data are expressed as patient’s number (%), or mean ± SD. A statistically significant difference was defined as < 0.05. 25-OHD, 25-hydroxyvitamin D; ETE, extrathyroidal extension.
